Heidelberg Pharma disclosed in its July 15 half-year report that the Phase I dose-escalation portion of the HDP-101 study has been completed across ten cohorts and that the recommended Phase II dose has been…
Biogen presented Phase 2 CELIA data for diranersen, an intrathecally administered antisense oligonucleotide designed to reduce tau protein production by targeting MAPT mRNA in early Alzheimer’s disease. The 60 mg dose slowed decline by…
AstraZeneca has entered an exclusive global license agreement with China-based Dizal Pharmaceutical for Zegfrovy (sunvozertinib), an oral, irreversible EGFR inhibitor for non-small cell lung cancer harboring EGFR exon 20 insertion mutations. The agreement carries…
Spero Therapeutics licensed ex-Greater China rights to SP001, also known as IBI355, a Phase 2-ready third-generation Fc-silent anti-CD40L antibody from Innovent Biologics. The transaction gives Spero global rights outside Greater China, while Innovent retains…
Q32 Bio reported positive 36-week topline data from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe alopecia areata.Bempikibart is a fully human anti-IL-7Rα monoclonal…
Roche’s discontinuation of tominersen in Huntington’s disease creates an important platform-level readthrough for Wave Life Sciences and its allele-selective antisense oligonucleotide candidate, WVE-003.The key distinction is biological selectivity. Tominersen was designed to lower total…
Agenus announced an oversubscribed private placement that could provide up to $340 million to support the registrational development of botensilimab plus balstilimab, also known as BOT/BAL, in neoadjuvant microsatellite-stable colon cancer. The financing includes…
The FDA approved subcutaneous Sarclisa (isatuximab-irfc) Escena across all existing Sarclisa IV indications in multiple myeloma. It is the first anticancer treatment administered via an on-body injector, and the first myeloma therapy available by…
Confluence Genetics launched Cas-CLEAR, a CRISPR-based therapeutic platform that employs Cas12a2 nucleases to recognize cancer-specific genetic signatures and, upon target recognition, trigger broad collateral cleavage of cellular DNA and RNA — selectively killing cells…
Fate Therapeutics reported that its off-the-shelf CD19 CAR T-cell therapy FT819 produced early clinical improvement in four patients with treatment-resistant systemic sclerosis within three months of administration. Patients demonstrated improvement in the modified Rodnan…
